H-Index
14
Scimago Lab
powered by Scopus
eISSN: 1941-5923
call: +1.631.629.4328
Mon-Fri 10 am - 2 pm EST

Logo


Chordoma: A Case Report and Review of Literature

Unusual clinical course, Unusual or unexpected effect of treatment

Arish Noor, Poorva Bindal, Miguel Ramirez, James Vredenburgh

Internal Medicine, University of Connecticut, Farmington, CT, USA

Am J Case Rep 2020; 21:e918927

DOI: 10.12659/AJCR.918927

Available online:

Published: 2020-01-23


BACKGROUND: Chordoma is a rare, but aggressive bone tumor, primarily affecting the axial skeleton. Systemic chemotherapies are not effective against the tumor, and treatment primarily consists of surgical resection and radiation. Despite these treatment modalities, recurrence is common. Our case highlights the role of afatinib as an effective treatment option in such cases.
CASE REPORT: We present case of 68-year-old female with chordoma, who underwent multiple surgical resections, radiotherapy session, and had course complication by disease progression on imatinib and local recurrence. She was eventually placed on afatinib with good effect.
CONCLUSIONS: This article discusses the effectiveness of afatanib as a treatment modality, along with diagnosis, histopathological features, associated genetic aberrations, currently available and upcoming treatment options. Special emphasis is placed on molecular targeted therapy, emerging immunotherapies and use of vaccination in this field.

Keywords: chordoma, Molecular Targeted Therapy, proton therapy



Back